Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

4.7%

6 terminated/withdrawn out of 127 trials

Success Rate

87.8%

+1.2% vs industry average

Late-Stage Pipeline

26%

33 trials in Phase 3/4

Results Transparency

2%

1 of 43 completed trials have results

Key Signals

14 recruiting1 with results5 withdrawn

Enrollment Performance

Analytics

N/A
35(32.7%)
Phase 2
30(28.0%)
Phase 4
22(20.6%)
Phase 3
11(10.3%)
Phase 1
9(8.4%)
107Total
N/A(35)
Phase 2(30)
Phase 4(22)
Phase 3(11)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (127)

Showing 20 of 127 trials
NCT07629531Not ApplicableNot Yet Recruiting

Applied Research on a Non-pharmacological Intervention Program for Older Adults With Subjective Cognitive Decline

Role: lead

NCT07523659Recruiting

The Influence of Climate and Air Pollution on Physical Activity of Chinese People in Shenyang and Shenzhen

Role: collaborator

NCT07519837Not ApplicableRecruiting

Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics

Role: lead

NCT07518355Not ApplicableCompleted

Effects of Rutin on Oxidative Stress, Inflammatory Markers, and Blood Flow Velocity During Cycling 40km Time Trial Performance

Role: collaborator

NCT07503483Not ApplicableCompleted

The Effect of an Intrinsic Motivation-Based Mock Interview Workshop on Career Decision-Making Self-Efficacy in Nursing Students

Role: lead

NCT06013098Phase 4Completed

Effects of Different Oxygen Concentrations on Pulmonary Complications in Patients Undergoing Radical Resection of Esophageal Cancer

Role: lead

NCT07009223Not ApplicableRecruiting

Lifestyle Interventions to Prevent Cognitive Deficits in Subjects With Depressive Symptoms: From Mechanisms to Clinical Practice

Role: collaborator

NCT07388875Phase 2Not Yet Recruiting

Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC

Role: lead

NCT07376499Phase 2Not Yet Recruiting

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Role: lead

NCT07373964Phase 2Recruiting

A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

Role: lead

NCT06359106Phase 4Recruiting

Effects of Different Inhaled Oxygen Concentrations on Lung Function in Older Patients After Laparoscopic Gastrointestinal Surgery Under General Anesthesia

Role: lead

NCT06283134Phase 1Not Yet Recruiting

A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Role: lead

NCT07262840Not ApplicableRecruiting

Health Behavior Change in High-Risk Colorectal Cancer Individuals

Role: lead

NCT07118566Phase 2Not Yet Recruiting

Hyperthermia Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Gastrointestinal Malignancies With Liver Metastases

Role: lead

NCT06783933Active Not Recruiting

Artificial Intelligence-assisted Diagnosis

Role: collaborator

NCT07034391Phase 2Recruiting

A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status

Role: lead

NCT06991621Not ApplicableRecruiting

The Effect of Situation Puzzle Games on Nursing Students' Death Anxiety and Meaning in Life

Role: lead

NCT06951841Phase 4Not Yet Recruiting

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Role: lead

NCT06881017Phase 2Not Yet Recruiting

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Role: lead

NCT05015374Not ApplicableCompleted

Effect of Astaxanthin on the Patients With Alzheimer Disease

Role: collaborator